Company / FCF Margin
Kymera Therapeutics, Inc. FCF Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-597.6%
FY2025
5-year range
-597.6% / 592.1%
FY2021-FY2025
Trend
-35.7%
vs FY2024
Sector context
#114 of 133
Health Care
What the data says
Kymera Therapeutics, Inc.'s fcf margin of -597.6% is lower than 86% of companies in the Health Care sector (FY2025). Declined from -174.7% to -597.6% over the past 2 years.
Based on SEC 10-K filings.
-597.6% in FY2025 with a 5-year CAGR of -1189.8%.
Declined from -174.7% to -597.6% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -264.7pp
- 5-Year Change
- -1189.8pp
- 10-Year Change
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 133This company -597.6% Sector average -632.8%
▼
+5.6% above sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 35.7% year-over-year.
- Currently 35.2pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -597.6% | -35.7% |
| FY2024 | -440.5% | -152.1% |
| FY2023 | -174.7% | +47.5% |
| FY2022 | -333.0% | -156.2% |
| FY2021 | 592.1% | +0.0% |
| FY2020 | 592.1% | - |
| FY2019 | - | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026